<DOC>
	<DOCNO>NCT01088984</DOCNO>
	<brief_summary>The primary objective phase 1 study establish recommend phase II dose ( RP2D ) . The primary objective phase 2 study evaluate safety efficacy bendamustine recommend pediatric dose treatment pediatric patient relapse refractory acute leukemia .</brief_summary>
	<brief_title>Study Bendamustine Hydrochloride Treatment Pediatric Patients With Relapsed Refractory Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Key The patient histologically proven acute lymphocytic leukemia ( ALL ) acute myeloid leukemia ( AML ) relapse refractory last regimen , patient without alternative curative therapy . The patient 's last myelosuppression therapy end least 2 week first dose study drug . Nonhematologic acute toxic effect prior therapy resolve grade 2 less accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) . The patient adequate liver function bilirubin value less equal 1.5 time upper limit normal ( ULN ) aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) value less equal 5 time ageappropriate ULN . The patient adequate renal function serum creatinine value less 2 time ULN . The patient Karnofsky Lansky performance status 60 great . Patients older 16 year age score accord Karnofsky scale patient 16 year age younger score accord Lansky scale . The patient may hematopoietic stem cell transplantation . Women childbearing potential ( surgically sterile ) must use medically accept method contraception must agree continue use method duration treatment 30 day end treatment . Men surgically sterile capable produce offspring must practice abstinence use barrier method birth control , must agree continue use method duration treatment 30 day end treatment . The patient must willing able comply study restriction remain clinic require duration study period , willing return clinic followup evaluation specify protocol . Key The patient active , uncontrolled systemic infection , severe concurrent disease , symptomatic untreated central nervous system ( CNS ) involvement . The patient evidence active graft versus host disease . The patient know human immunodeficiency virus ( HIV ) infection . The patient active hepatitis B hepatitis C infection . The patient pregnant lactate woman . Any woman become pregnant study withdrawn study immediately . The patient serious uncontrolled medical psychological disorder would impair ability patient receive study drug . The patient condition place patient unacceptable risk confounds ability investigator interpret study data . The patient receive investigational agent within 30 day study entry . The patient know hypersensitivity bendamustine mannitol .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>